# Geneos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geneos-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.geneostx.com
- Total disclosed funding: $50M
- Latest round: Series A (Sep 27, 2023)
- Investors on record: 6

## About

Founded in 2017 and based in Pennsylvania, US, Geneos Therapeutics, Inc. operates as a developer of immunotherapies targeting neoantigens from tumors which serves as a treatment for cancer. The company was founded by its President and Chief Executive Officer Niranjan Y. Sardesai. In March 2023, Geneos Therapeutics, Inc. raised USD 4.9 million in series A funding from 3B Future Health Fund.

Geneos has a neoantigen-targeting platform called GT-EPIC™ that is based on a DNA medicines technology licensed from Inovio Pharmaceuticals, Inc. The GT-EPIC™ platform allows Geneos to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer. As of 2021, the company is pursuing three clinical pipeline programs: GT-10, GT-20, and GT-30. GT-10 is a clinical trial for Geneos’s neoantigen-targeted personalized vaccine, GNOS-PV02 for the treatment of a patient with anaplastic astrocytoma. GT-20 is a clinical trial in collaboration with Washington University to treat patients with newly diagnosed glioblastoma multiforme and GT-30 is a clinical trial to treat patients with hepatocellular carcinoma. 

The company intends to use the March 2023 funding to support its customized clinical trial.

## Funding rounds

- Series A, Sep 27, 2023, $5M — Shanghai Healthcare Capital
- Series A, Mar 31, 2023, $5M — 3B Future Health Fund
- Series A, Mar 21, 2022, $17M — Sante Ventures, Korea Investment Partners, Inovio Pharmaceuticals, Inc., Flerie Invest
- Series A, Mar 3, 2021, $12M — Sante Ventures, Korea Investment Partners, Inovio Pharmaceuticals, Inc.
- Series A, Feb 21, 2019, $11M — Sante Ventures, Inovio Pharmaceuticals, Inc.

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A
- Inovio Pharmaceuticals, Inc. — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- Flerie Invest (https://capitalatlas.ai/funds/flerie-invest) — Series A
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series A
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series A